HR Execs on the Move

Syneos Health

www.syneoshealth.com

 
"Syneos Health® (Nasdaq:SYNH) is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers` delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Chris Hodes
 Regional Sales Director Profile
Steve O'Brien
 SVP, Talent Acquisition Profile
Hillary Bochniak
 Chief Human Resources Officer Profile
Robyn Aycock
 Regional Sales Director-Southeast Profile
Stanford Rudnick
 Interim Chief Financial Officer and Chief Strategy Officer Profile

Similar Companies

Mega Aid Compounding Pharmacy

Mega Aid is a full service specialty and compounding pharmacy, serving physicians and their patients.

River Remedy

River Remedy is a medical cannabis company dedicated to serving Mississippi patients with the highest quality plant based medicine.

Chembio Diagnostic Systems

Chembio Diagnostic Systems, Inc. is a Medford, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Karuna Pharmaceuticals

Karuna Pharmaceuticals is a clinical-stage company targeting muscarinic cholinergic receptors for the treatment of psychosis and cognitive impairment across central nervous system (CNS) disorders.

Berg Pharma

Berg Pharma focuses research on understanding how alterations in metabolism relate to disease onset. The company has a deep pipeline of early-stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with use of the Berg Interrogative Biology™ discovery platform that translates biological output into therapeutic candidates, Berg Pharma is well positioned for rapid commercialization of its intellectual capital.